Suboptimal engagement of the T-cell receptor by a variety of peptide-MHC ligands triggers T-cell anergy

Immunology

Volumn 129, Issue 1, 2010, Pages 1-7

  Sadegh Nasseri, Scheherazade ^a   Dalai, Sarat K ^a,b   Korb Ferris, Laura C ^a,c   Mirshahidi, Saied ^a,d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^c Department of Dermatology ^*  (United States)

^d LOMA LINDA UNIVERSITY   (United States)

Author keywords

Altered peptide ligand; Avidity; Memory T cells; Regulation; T cell receptor

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN; PEPTIDE; T LYMPHOCYTE RECEPTOR;

ANTIGEN PRESENTATION; CD4+ T LYMPHOCYTE; CLONAL ANERGY; HUMAN; IN VIVO STUDY; MEMORY T LYMPHOCYTE; MOLECULAR DOCKING; MOLECULAR MECHANICS; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIGENS; CD4-POSITIVE T-LYMPHOCYTES; CLONAL ANERGY; HISTOCOMPATIBILITY ANTIGENS; HUMANS; IMMUNE TOLERANCE; IMMUNOLOGIC MEMORY; MODELS, IMMUNOLOGICAL; PEPTIDE FRAGMENTS; PROTEIN BINDING; RECEPTORS, ANTIGEN, T-CELL; SIGNAL TRANSDUCTION; T-CELL ANTIGEN RECEPTOR SPECIFICITY;

EID: 71749102083     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2009.03206.x     Document Type: Review

References (83)

1. Mathis D, Benoist C. Aire. Annu Rev Immunol 2009 27: 287 312.
2. Josefowicz SZ, Rudensky A. Control of regulatory T cell lineage commitment and maintenance. Immunity 2009 30: 616 625.
3. Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol 2008 8: 523 532.
4. Schwartz RH. T cell anergy. Annu Rev Immunol 2003 21: 305 334.
5. Jenkins MK, Schwartz RH. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J Exp Med 1987 165: 302 319.
6. De Magistris MT, Alexander J, Coggeshall M, Altman A, Gaeta FC, Grey HM, Sette A. Antigen analog-major histocompatibility complexes act as antagonists of the T cell receptor. Cell 1992 68: 625 634.
7. Sloan-Lancaster J, Evavold BD, Allen PM. Induction of T-cell anergy by altered T-cell-receptor ligand on live antigen-presenting cells. Nature 1993 363: 156 159.
8. Madrenas J, Wange RL, Wang JL, Isakov N, Samelson LE, Germain RN. Zeta phosphorylation without zap-70 activation induced by TCR antagonists or partial agonists. Science 1995 267: 515 518.
9. Racioppi L, Ronchese F, Matis LA, Germain RN. Peptide-major histocompatibility complex class II complexes with mixed agonistantagonist properties provide evidence for ligand-related differences in T CELL receptor-dependent intracellular signaling. J Exp Med 1993 177: 1047 1060.
10. Evavold BD, Allen PM. Separation of IL-4 production from Th cell proliferation by an altered T CELL receptor ligand. Science 1991 252: 1308 1310.
11. Evavold BD, Sloan-Lancaster J, Allen PM. Tickling the TCR: selective t-cell functions stimulated by altered peptide ligands. Immunol Today 1993 14: 602 609.
12. Sloan-Lancaster J, Shaw AS, Rothbard JB, Allen PM. Partial T cell signaling: altered phospho-zeta and lack of zap70 recruitment in APL-induced T cell anergy. Cell 1994 79: 913 922.
13. Ding YH, Baker BM, Garboczi DN, Biddison WE, Wiley DC. Four A6-TCRpeptideHLA-A2 structures that generate very different T cell signals are nearly identical. Immunity 1999 11: 45 56.
14. Baker BM, Gagnon SJ, Biddison WE, Wiley DC. Conversion of a T cell antagonist into an agonist by repairing a defect in the TCRpeptideMHC interface: implications for TCR signaling. Immunity 2000 13: 475 484.
15. Matsui K, Boniface JJ, Steffner P, Reay PA, Davis MM. Kinetics of t-cell receptor binding to peptideI-Ek complexes: correlation of the dissociation rate with t-cell responsiveness. Proc Natl Acad Sci U S A 1994 91: 12862 12866.
16. Rudolph MG, Stanfield RL, Wilson IA. How TCRs bind MHCs, peptides, and coreceptors. Annu Rev Immunol 2006 24: 419 466.
17. Schuck P. Reliable determination of binding affinity and kinetics using surface plasmon resonance biosensors. Curr Opin Biotechnol 1997 8: 498 502.
18. Schuck P. Use of surface plasmon resonance to probe the equilibrium and dynamic aspects of interactions between biological macromolecules. Annu Rev Biophys Biomol Struct 1997 26: 541 566.
19. Alam SM, Travers PJ, Wung JL, Nasholds W, Redpath S, Jameson SC, Gascoigne NR. T-cell-receptor affinity and thymocyte positive selection. Nature 1996 381: 616 620.
20. Rabinowitz JD, Beeson C, Lyons DS, Davis MM, McConnell HM. Kinetic discrimination in t-cell activation. Proc Natl Acad Sci U S A 1996 93: 1401 1405.
21. Lyons DS, Lieberman SA, Hampl J, Boniface JJ, Chien Y, Berg LJ, Davis MM. A TCR binds to antagonist ligands with lower affinities and faster dissociation rates than to agonists. Immunity 1996 5: 53 61.
22. Kersh GJ, Kersh EN, Fremont DH, Allen PM. High-and low-potency ligands with similar affinities for the TCR: the importance of kinetics in TCR signaling. Immunity 1998 9: 817 826.
23. Germain RN, Stefanova I. The dynamics of T cell receptor signaling: complex orchestration and the key roles of tempo and cooperation. Annu Rev Immunol 1999 17: 467 522.
24. Boniface JJ, Rabinowitz JD, Wulfing C et al. Initiation of signal transduction through the T cell receptor requires the multivalent engagement of peptideMHC ligands [corrected]. Immunity 1998 9: 459 466. (Pubitemid 28499197)
25. Beeson C, Rabinowitz J, Tate K, Gutgemann I, Chien YH, Jones PP, Davis MM, McConnell HM. Early biochemical signals arise from low affinity TCR-ligand reactions at the cell-cell interface. J Exp Med 1996 184: 777 782.
26. Rabinowitz JD, Beeson C, Wulfing C, Tate K, Allen PM, Davis MM, McConnell HM. Altered T cell receptor ligands trigger a subset of early T cell signals. Immunity 1996 5: 125 135.
27. Rosette C, Werlen G, Daniels MA et al. The impact of duration versus extent of TCR occupancy on T cell activation: a revision of the kinetic proofreading model. Immunity 2001 15: 59 70.
28. Sykulev Y, Vugmeyster Y, Brunmark A, Ploegh HL, Eisen HN. Peptide antagonism and T cell receptor interactions with peptide-MHC complexes. Immunity 1998 9: 475 483.
29. Rudolph MG, Luz JG, Wilson IA. Structural and thermodynamic correlates of T cell signaling. Annu Rev Biophys Biomol Struct 2002 31: 121 149.
30. Mirshahidi S, Ferris LC, Sadegh-Nasseri S. The magnitude of TCR engagement is a critical predictor of T cell anergy or activation. J Immunol 2004 172: 5346 5355.
31. Jardetzky TS, Gorga JC, Busch R, Rothbard J, Strominger JL, Wiley DC. Peptide binding to HLA-DR1: a peptide with most residues substituted to Alanine retains MHC binding. EMBO J 1990 9: 1797 1803.
32. Natarajan SK, Stern LJ, Sadegh-Nasseri S. Sodium dodecyl sulfate stability of HLA-DR1 complexes correlates with burial of hydrophobic residues in pocket 1. J Immunol 1999 162: 3463 3470.
33. Mirshahidi S, Huang CT, Sadegh-Nasseri S. Anergy in peripheral memory CD4(+) T cells induced by low avidity engagement of T cell receptor. J Exp Med 2001 194: 719 731.
34. Korb LC, Mirshahidi S, Ramyar K, Sadighi Akha AA, Sadegh-Nasseri S. Induction of T cell anergy by low numbers of agonist ligands. J Immunol 1999 162: 6401 6409.
35. Ryan KR, McNeil LK, Dao C, Jensen PE, Evavold BD. Modification of peptide interaction with MHC creates TCR partial agonists. Cell Immunol 2004 227: 70 8.
36. Ford ML, Evavold BD. Regulation of polyclonal T cell responses by an MHC anchor-substituted variant of myelin oligodendrocyte glycoprotein 35-55. J Immunol 2003 171: 1247 1254.
37. Robertson JM, Evavold BD. Cutting edge: dueling TCRs: peptide antagonism of CD4+ T cells with dual antigen specificities. J Immunol 1999 163: 1750 1754.
38. Ryan KR, Evavold BD. Persistence of peptide-induced CD4+ T cell anergy in vitro. J Exp Med 1998 187: 89 96.
39. Valitutti S, Muller S, Cella M, Padovan E, Lanzavecchia A. Serial triggering of many t-cell receptors by a few peptide-MHC complexes. Nature 1995 375: 148 151.
40. Valitutti S, Muller S, Salio M, Lanzavecchia A. Degradation of T cell receptor (TCR)-CD3-zeta complexes after antigenic stimulation. J Exp Med 1997 185: 1859 1864.
41. Sykulev Y, Joo M, Vturina I, Tsomides TJ, Eisen HN. Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response. Immunity 1996 4: 565 571.
42. Irvine DJ, Purbhoo MA, Krogsgaard M, Davis MM. Direct observation of ligand recognition by T cells. Nature 2002 419: 845 849.
43. Valitutti S, Muller S, Dessing M, Lanzavecchia A. Different responses are elicited in cytotoxic t lymphocytes by different levels of T cell receptor occupancy. J Exp Med 1996 183: 1917 1921.
44. Fields PE, Gajewski TF, Fitch FW. Blocked Ras activation in anergic CD4+ T cells. Science 1996 271: 1276 1278.
45. Clements JL, Boerth NJ, Lee JR, Koretzky GA. Integration of T CELL receptor-dependent signaling pathways by adapter proteins. Annu Rev Immunol 1999 17: 89 108.
46. Huang J, Tilly D, Altman A, Sugie K, Grey HM. T-cell receptor antagonists induce Vav phosphorylation by selective activation of Fyn kinase. Proc Natl Acad Sci U S A 2000 97: 10923 10929.
47. Villalba M, Coudronniere N, Deckert M, Teixeiro E, Mas P, Altman A. A novel functional interaction between Vav and PKC theta is required for TCR-induced T CELL activation. Immunity 2000 12: 151 160.
48. Villalba M, Hernandez J, Deckert M, Tanaka Y, Altman A. Vav modulation of the RasMekErk signaling pathway plays a role in NFAT activation and CD69 up-regulation. Eur J Immunol 2000 30: 1587 1596.
49. Villalba M, Bi K, Rodriguez F, Tanaka Y, Schoenberger S, Altman A. Vav1rac-dependent actin cytoskeleton reorganization is required for lipid raft clustering in T cells. J Cell Biol 2001 155: 331 338.
50. Wulfing C, Bauch A, Crabtree GR, Davis MM. The vav exchange factor is an essential regulator in actin-dependent receptor translocation to the lymphocyte-antigen-presenting cell interface. Proc Natl Acad Sci U S A 2000 97: 10150 10155.
51. Holsinger LJ, Graef IA, Swat W et al. Defects in actin-cap formation in Vav-deficient mice implicate an actin requirement for lymphocyte signal transduction. Curr Biol 1998 8: 563 572.
52. Penninger JM, Fischer KD, Sasaki T et al. The oncogene product Vav is a crucial regulator of primary cytotoxic T cell responses but has no apparent role in CD28-mediated co-stimulation. Eur J Immunol 1999 29: 1709 1718.
53. Valitutti S, Lanzavecchia A. Serial triggering of TCRs: a basis for the sensitivity and specificity of antigen recognition. Immunol Today 1997 18: 299 304.
54. Kersh GJ, Miley MJ, Nelson CA et al. Structural and functional consequences of altering a peptide MHC anchor residue. J Immunol 2001 166: 3345 3354.
55. Sette A, Alexander J, Ruppert J, Snoke K, Franco A, Ishioka G, Grey HM. Antigen analogsMHC complexes as specific T cell receptor antagonists. Annu Rev Immunol 1994 12: 413 431.
56. Hampl J, Chien YH, Davis MM. CD4 augments the response of a T cell to agonist but not to antagonist ligands. Immunity 1997 7: 379 385.
57. Rosloniec EF, Brand DD, Myers LK et al. An HLA-DR1 transgene confers susceptibility to collagen-induced arthritis elicited with human type II collagen. J Exp Med 1997 185: 1113 1122.
58. Hataye J, Moon JJ, Khoruts A, Reilly C, Jenkins MK. Naive and memory CD4+ T cell survival controlled by clonal abundance. Science 2006 312: 114 116.
59. Badovinac VP, Haring JS, Harty JT. Initial T cell receptor transgenic cell precursor frequency dictates critical aspects of the CD8(+) T cell response to infection. Immunity 2007 26: 827 841.
60. Ford ML, Koehn BH, Wagener ME, Jiang W, Gangappa S, Pearson TC, Larsen CP. Antigen-specific precursor frequency impacts T cell proliferation, differentiation, and requirement for costimulation. J Exp Med 2007 204: 299 309.
61. Marzo AL, Klonowski KD, Le Bon A, Borrow P, Tough DF, Lefrancois L. Initial T cell frequency dictates memory CD8+ T cell lineage commitment. Nat Immunol 2005 6: 793 799.
62. Dalai SK, Mirshahidi S, Morrot A, Zavala F, Sadegh-Nasseri S. Anergy in memory CD4+ T cells is induced by B cells. J Immunol 2008 181: 3221 3231.
63. Bielekova B, Goodwin B, Richert N et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase ii clinical trial with an altered peptide ligand. Nat Med 2000 6: 1167 1175.
64. Kappos L, Comi G, Panitch H, Oger J, Antel J, Conlon P, Steinman L. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The altered peptide ligand in relapsing ms study group. Nat Med 2000 6: 1176 1182.
65. Dutton RW, Bradley LM, Swain SL. T cell memory. Annu Rev Immunol 1998 16: 201 223.
66. Bachmann MF, Barner M, Viola A, Kopf M. Distinct kinetics of cytokine production and cytolysis in effector and memory T cells after viral infection. Eur J Immunol 1999 29: 291 299.
67. London CA, Perez VL, Abbas AK. Functional characteristics and survival requirements of memory CD4+ T lymphocytes in vivo. J Immunol 1999 162: 766 773.
68. London CA, Lodge MP, Abbas AK. Functional responses and costimulator dependence of memory CD4+ T cells. J Immunol 2000 164: 265 272.
69. Kersh EN, Kaech SM, Onami TM, Moran M, Wherry EJ, Miceli MC, Ahmed R. TCR signal transduction in antigen-specific memory CD8 T cells. J Immunol 2003 170: 5455 5463.
70. Slifka MK, Whitton JL. Functional avidity maturation of CD8(+) T cells without selection of higher affinity TCR. Nat Immunol 2001 2: 711 717.
71. Farber DL. Biochemical signaling pathways for memory T cell recall. Semin Immunol 2009 21: 84 91.
72. Macleod MK, Clambey ET, Kappler JW, Marrack P. CD4 memory T cells: what are they and what can they do? Semin Immunol 2009 21: 53 61.
73. Bachmann MF, Gallimore A, Linkert S, Cerundolo V, Lanzavecchia A, Kopf M, Viola A. Developmental regulation of lck targeting to the CD8 coreceptor controls signaling in naive and memory T cells. J Exp Med 1999 189: 1521 1530.
74. Crowe SR, Turner SJ, Miller SC, Roberts AD, Rappolo RA, Doherty PC, Ely KH, Woodland DL. Differential antigen presentation regulates the changing patterns of CD8+ T cell immunodominance in primary and secondary influenza virus infections. J Exp Med 2003 198: 399 410.
75. Wang C, Lin GH, McPherson AJ, Watts TH. Immune regulation by 4-1BB and 4-1BBl: complexities and challenges. Immunol Rev 2009 229: 192 215.
76. Zammit DJ, Cauley LS, Pham QM, Lefrancois L. Dendritic cells maximize the memory CD8 T cell response to infection. Immunity 2005 22: 561 570.
77. Selin LK, Brehm MA, Naumov YN, Cornberg M, Kim SK, Clute SC, Welsh RM. Memory of mice and men: Cd8+ t-cell cross-reactivity and heterologous immunity. Immunol Rev 2006 211: 164 181.
78. Marrack P, Kappler J. Control of T cell viability. Annu Rev Immunol 2004 22: 765 787.
79. Marsden VS, Kappler JW, Marrack PC. Homeostasis of the memory T cell pool. Int Arch Allergy Immunol 2006 139: 63 74.
80. Lanzavecchia A. Antigen-specific interaction between t and b cells. Nature 1985 314: 537 539.
81. Granucci F, Feau S, Angeli V, Trottein F, Ricciardi-Castagnoli P. Early IL-2 production by mouse dendritic cells is the result of microbial-induced priming. J Immunol 2003 170: 5075 5081.
82. Brodsky FM, Lem L, Solache A, Bennett EM. Human pathogen subversion of antigen presentation. Immunol Rev 1999 168: 199 215.
83. Topalian SL, Gonzales MI, Parkhurst M, Li YF, Southwood S, Sette A, Rosenberg SA, Robbins PF. Melanoma-specific CD4+ T cells recognize nonmutated hla-dr-restricted tyrosinase epitopes. J Exp Med 1996 183: 1965 1971.